Patents by Inventor Kenneth C. Cundy

Kenneth C. Cundy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic peptides
    Patent number: 11332497
    Abstract: Provided herein are peptides and peptide analogs and methods of treating a metabolic disease, e.g., obesity, diabetes, methods of treating cancer, methods of treating a liver disease, and methods of modulating fatty acid metabolism.
    Type: Grant
    Filed: August 4, 2021
    Date of Patent: May 17, 2022
    Assignee: COHBAR, INC.
    Inventors: Kenneth C. Cundy, Kent K. Grindstaff, Remi Magnan, Wendy Luo, Yongjin Yao, Liang Zeng Yan
  • THERAPEUTIC PEPTIDES
    Publication number: 20210363187
    Abstract: Provided herein are peptides and peptide analogs and methods of treating a metabolic disease, e.g., obesity, diabetes, methods of treating cancer, methods of treating a liver disease, and methods of modulating fatty acid metabolism.
    Type: Application
    Filed: August 4, 2021
    Publication date: November 25, 2021
    Inventors: Kenneth C. Cundy, Kent K. Grindstaff, Remi Magnan, Wendy Luo, Yongjin Yao, Liang Zeng Yan
  • Therapeutic peptides
    Patent number: 11111271
    Abstract: Provided herein are peptides and peptide analogs and methods of treating a metabolic disease, e.g., obesity, diabetes, methods of treating cancer, methods of treating a liver disease, and methods of modulating fatty acid metabolism.
    Type: Grant
    Filed: September 27, 2017
    Date of Patent: September 7, 2021
    Assignee: COHBAR, INC.
    Inventors: Kenneth C. Cundy, Kent K. Grindstaff, Remi Magnan, Wendy Luo, Yongjin Yao, Liang Zeng Yan
  • Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects
    Publication number: 20210228525
    Abstract: Methods of reducing undesirable side effects during therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed.
    Type: Application
    Filed: February 3, 2021
    Publication date: July 29, 2021
    Inventors: Kenneth C. Cundy, Sami Karaborni, Peter A. Virsik
  • Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
    Patent number: 10945984
    Abstract: Methods of reducing undesirable side effects during therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed.
    Type: Grant
    Filed: August 22, 2013
    Date of Patent: March 16, 2021
    Assignee: Arbor Pharmaceuticals, LLC
    Inventors: Kenneth C. Cundy, Sami Karaborni, Peter A. Virsik
  • GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS
    Publication number: 20200323804
    Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
    Type: Application
    Filed: June 25, 2020
    Publication date: October 15, 2020
    Inventors: Kenneth C. Cundy, Srikonda Sastry, Manshiu Leung, Balaji V. Kadri, Paul E. Stach
  • THERAPEUTIC PEPTIDES
    Publication number: 20200181197
    Abstract: Provided herein are peptides and peptide analogs and methods of treating a metabolic disease, e.g., obesity, diabetes, methods of treating cancer, methods of treating a liver disease, and methods of modulating fatty acid metabolism.
    Type: Application
    Filed: September 27, 2017
    Publication date: June 11, 2020
    Inventors: Kenneth C. Cundy, Kent K. Grindstaff, Remi Magnan, Wendy Luo, Yongjin Yao, Liang Zeng Yan
  • GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS
    Publication number: 20200147019
    Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
    Type: Application
    Filed: October 15, 2019
    Publication date: May 14, 2020
    Inventors: Kenneth C. Cundy, Srikonda Sastry, Manshiu Leung, Balaji V. Kadri, Paul E. Stach
  • GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS
    Publication number: 20190247345
    Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
    Type: Application
    Filed: December 10, 2018
    Publication date: August 15, 2019
    Inventors: Kenneth C. Cundy, Srikonda Sastry, Manshiu Leung, Balaji V. Kadri, Paul E. Stach
  • GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS
    Publication number: 20180207117
    Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
    Type: Application
    Filed: March 19, 2018
    Publication date: July 26, 2018
    Inventors: Kenneth C. Cundy, Srikonda Sastry, Manshiu Leung, Balaji V. Kadri, Paul E. Stach
  • GABA analog prodrug sustained release oral dosage forms
    Patent number: 9949941
    Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: April 24, 2018
    Assignee: XENOPORT, INC.
    Inventors: Kenneth C. Cundy, Srikonda Sastry, Manshiu Leung, Balaji V. Kadri, Paul E. Stach
  • GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS
    Publication number: 20170071888
    Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
    Type: Application
    Filed: November 22, 2016
    Publication date: March 16, 2017
    Inventors: Kenneth C. Cundy, Srikonda Sastry, Manshiu Leung, Balaji V. Kadri, Paul E. Stach
  • METHODS OF ADMINISTERING MONOMETHYL FUMARATE
    Publication number: 20150190360
    Abstract: Methods of therapeutic treatment using monomethyl fumarate are disclosed.
    Type: Application
    Filed: March 18, 2015
    Publication date: July 9, 2015
    Inventor: Kenneth C. Cundy
  • GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS
    Publication number: 20150072004
    Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
    Type: Application
    Filed: November 4, 2014
    Publication date: March 12, 2015
    Inventors: Kenneth C. Cundy, Srikonda Sastry, Manshiu Leung, Balaji V. Kadri, Paul E. Stach
  • Morpholinoalkyl fumarate compounds, pharmaceutical compositions, and methods of use
    Patent number: 8952006
    Abstract: Morpholinoalkyl fumarates, pharmaceutical compositions comprising the morpholinoalkyl fumarates, and methods of using morpholinoalkyl fumarates and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are disclosed.
    Type: Grant
    Filed: February 7, 2013
    Date of Patent: February 10, 2015
    Assignee: XenoPort, Inc.
    Inventors: Kenneth C. Cundy, Suresh K. Manthati, David J. Wustrow
  • GABA analog prodrug sustained release oral dosage forms
    Patent number: 8906412
    Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: December 9, 2014
    Assignee: XenoPort, Inc.
    Inventors: Kenneth C. Cundy, Srikonda Sastry, Manshiu Leung, Balaji V. Kadri, Paul E. Stach
  • Methods of Administering Monomethyl Fumarate and Prodrugs Thereof Having Reduced Side Effects
    Publication number: 20140350018
    Abstract: Methods of reducing undesirable side effects during therapeutic treatment using monomethyl fumarate and prodrugs of monomethyl fumarate are disclosed.
    Type: Application
    Filed: August 22, 2013
    Publication date: November 27, 2014
    Applicant: XenoPort, Inc.
    Inventors: Kenneth C. Cundy, Sami Karaborni, Peter A. Virsik
  • GABA ANALOG PRODRUG SUSTAINED RELEASE ORAL DOSAGE FORMS
    Publication number: 20140302140
    Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
    Type: Application
    Filed: June 19, 2014
    Publication date: October 9, 2014
    Inventors: Kenneth C. Cundy, Srikonda Sastry, Manshiu Leung, Balaji V. Kadri, Paul E. Stach
  • Methods of Administering Monomethyl Fumarate
    Publication number: 20140275250
    Abstract: Methods of therapeutic treatment using monomethyl fumarate are disclosed.
    Type: Application
    Filed: August 22, 2013
    Publication date: September 18, 2014
    Applicant: XenoPort, Inc.
    Inventor: Kenneth C. Cundy
  • GABA analog prodrug sustained release oral dosage forms
    Patent number: 8795725
    Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
    Type: Grant
    Filed: November 3, 2005
    Date of Patent: August 5, 2014
    Assignee: XenoPort, Inc.
    Inventors: Kenneth C. Cundy, Srikonda Sastry, Manshiu Leung, Balaji V. Kadri, Paul E. Stach